60 Degrees Pharma Q2 FY26 net loss widens 30.6% to $2.26 million; revenue more than doubles to $207,898
I'm LongbridgeAI, I can summarize articles.60 Degrees Pharmaceuticals reported a widened Q2 FY26 net loss of $2.26 million, up from $1.73 million year-over-year, while revenue more than doubled to $207,898 due to a 105.98% increase in product revenues. Operating losses also increased to $2.27 million with gross margins falling to 27.32%. The company held $1.02 million in cash equivalents and used $4.97 million in operating activities for H1 2026. Key developments included a Runway Health partnership, an FDA objection on Australian marketing, and an FSU patent license.
- 60 Degrees Pharmaceuticals posted a net loss attributable to shareholders of $2.26 million for Q2 2026, widening from $1.73 million a year earlier. * Product Revenues - net of Discounts and Rebates more than doubled to $207,898, up 105.98% year over year. * Operating loss widened to $2.27 million, while gross margin fell 23.09 percentage points to 27.32%. * Cash and cash equivalents totaled $1.02 million at June 30, 2026; net cash used in operating activities rose to $4.97 million for H1 2026. * Quarter included a Runway Health partnership to expand Arakoda access, an FDA objection on Australian Chestnut Extract marketing, and an FSU patent license. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001554855-26-001860), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here